PharmaShots | Incisive News in 3 Shots

Subscribe Now

P-IIb

Denali Therapeutics and Biogen Initiate P-IIb (LUMA) Study of BIIB122 for the Treatment of Parkinson’s Disease

Denali Therapeutics and Biogen Initiate P-IIb (LUMA) Study of BIIB122 for the Treatment of Parkinson’s Disease

June 1, 2022

Hepion Collaborates with HepQuant for P-IIb Study of Rencofilstat (CRV431) in NASH

Hepion Collaborates with HepQuant for P-IIb Study of Rencofilstat (CRV431) in NASH

May 4, 2022

Imara to Discontinue P-IIb (Ardent & Forte) Trial of Tovinontrine (IMR-687) for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Imara to Discontinue P-IIb (Ardent & Forte) Trial of Tovinontrine (IMR-687) for the Treatment of Sickle Cell Disease and Beta-Thal...

April 5, 2022

Ionis and AstraZeneca Reports Results of P-IIb (ETESIAN) Study of ION449 for the Treatment of Hypercholesterolemia at ACC 2022

Ionis and AstraZeneca Reports Results of P-IIb (ETESIAN) Study of ION449 for the Treatment of Hypercholesterolemia at ACC 2022

April 4, 2022

Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis

Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis

February 21, 2022

Timber Reports Completion of End-of-P-II Meeting with the US FDA for to Treat Congenital Ichthyosis

Timber Reports Completion of End-of-P-II Meeting with the US FDA for to Treat Congenital Ichthyosis

February 4, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us